Study budgets and site identification and selection processes continue to result in study timelines being extended and a significant loss of experienced investigators. Senior executives from industry will discuss how identification and selection processes can be improved as well as how to achieve real fair market value in site study budgets and payment terms. These methods and processes continue to cause a dramatic reduction in the number of GCP-qualified US-based investigators and have dramatically extended study timelines and added significant cost to Pharma, resulting in severe Pharma employee reductions and cost shifting of R&D expense to CROs. It remains to be seen if this strategy will result in increased productivity.

Learning Objectives:
Discuss how study budgets are formulated and developed and how they can be improved
Explain how sites can be better identified and selected
Describe how the processes for site identification and selection can be improved with Pharma and CROs.